Rezolute, Inc. $RZLT Shares Acquired by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors increased its Rezolute stake by 273.7% in the first quarter, reaching 530,229 shares valued at approximately $1.62 million. Institutional investors collectively own 82.97% of the company.
• Analyst sentiment is generally positive, with eight Buy ratings, two Holds and two Sells; Rezolute has a consensus “Moderate Buy” rating and an average price target of $9.38.
• Rezolute shares opened at $4.60, compared with a 12-month range of $1.07 to $11.46. The clinical-stage biopharmaceutical company is advancing RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema.

Dimensional Fund Advisors LP increased its position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 273.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 530,229 shares of the company's stock after purchasing an additional 388,346 shares during the quarter. Dimensional Fund Advisors LP owned 0.55% of Rezolute worth $1,617,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Federated Hermes Inc. grew its stake in Rezolute by 17.8% in the fourth quarter. Federated Hermes Inc. now owns 16,534,712 shares of the company's stock worth $39,022,000 after purchasing an additional 2,500,000 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Rezolute during the fourth quarter worth about $21,665,000. Opaleye Management Inc. grew its position in shares of Rezolute by 595.9% during the fourth quarter. Opaleye Management Inc. now owns 6,287,156 shares of the company's stock worth $14,838,000 after acquiring an additional 5,383,714 shares during the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of Rezolute by 147.3% in the 4th quarter. Balyasny Asset Management L.P. now owns 4,506,861 shares of the company's stock worth $10,636,000 after acquiring an additional 2,684,133 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Rezolute by 9.6% in the 3rd quarter. Vanguard Group Inc. now owns 4,410,082 shares of the company's stock worth $41,455,000 after acquiring an additional 387,502 shares during the period. Hedge funds and other institutional investors own 82.97% of the company's stock.

Wall Street Analyst Weigh In

RZLT has been the topic of a number of recent analyst reports. Citizens Jmp upgraded shares of Rezolute from a "market perform" rating to an "outperform" rating and set a $11.00 price objective on the stock in a research note on Wednesday, June 3rd. HC Wainwright reaffirmed a "buy" rating on shares of Rezolute in a report on Thursday, July 30th. Guggenheim raised their price objective on Rezolute from $6.00 to $11.00 and gave the stock a "buy" rating in a research report on Monday, June 15th. Wall Street Zen downgraded Rezolute from a "hold" rating to a "sell" rating in a research note on Tuesday, June 30th. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of Rezolute in a report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $9.38.

Rezolute Stock Down 2.1%

Rezolute stock opened at $4.60 on Friday. The stock has a market capitalization of $442.93 million, a price-to-earnings ratio of -5.61 and a beta of 0.58. Rezolute, Inc. has a 12-month low of $1.07 and a 12-month high of $11.46. The stock has a 50-day simple moving average of $4.75 and a 200 day simple moving average of $3.78.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.01. As a group, sell-side analysts anticipate that Rezolute, Inc. will post -0.69 EPS for the current year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source